Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, Melanoma and MAPK Pathways, and Breast Cancer Treatment Studies.
SlideCNA: spatial copy number alteration detection from Slide-seq-like spatial transcriptomics data
Author Correction: A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
137P First-in-human results from a phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation
A patient-driven clinicogenomic partnership for metastatic prostate cancer
Abstract PD6-03: Spatio-molecular dissection of the breast cancer metastatic microenvironment
Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Hotspot <i>ESR1</i> mutations are multimodal and contextual drivers of breast cancer metastasis
A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Expansion Sequencing: Spatially Precise <i>In Situ</i> Transcriptomics in Intact Biological Systems
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine